LDLR and familial hyperaldosteronism: In this study, we used both untargeted mass spectrometry-based lipidomics and NMR-based metabolomics approaches to assess the plasma profiles in patients with HeFH characterized by pathogenic variants in the LDLR gene that are known to impair LDL clearance and result in elevated cholesterol levels, in parallel with FH/V−/USV− patients for whom the molecular bases of FH are not related to a specific pathogenic variant and/or remain unclear.